5.20
Schlusskurs vom Vortag:
$5.23
Offen:
$5.2
24-Stunden-Volumen:
99,396
Relative Volume:
0.01
Marktkapitalisierung:
$9.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.75M
KGV:
-1.60
EPS:
-3.25
Netto-Cashflow:
$-30.91M
1W Leistung:
+8.79%
1M Leistung:
+1,682%
6M Leistung:
+2,005%
1J Leistung:
+72.19%
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
Cellectar Biosciences Inc
Sektor
Branche
Telefon
(608) 441-8120
Adresse
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Vergleichen Sie CLRB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CLRB
Cellectar Biosciences Inc
|
5.20 | 13.66M | 0 | -37.75M | -30.91M | -3.25 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy |
2020-07-01 | Eingeleitet | Oppenheimer | Outperform |
2020-01-21 | Fortgesetzt | ROTH Capital | Buy |
2019-09-13 | Eingeleitet | ROTH Capital | Buy |
2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Cellectar Biosciences Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com
What analysts say about Cellectar Biosciences Inc. stockExceptional trading performance - Autocar Professional
What drives Cellectar Biosciences Inc. stock priceHigh-yield portfolio picks - Autocar Professional
Is Cellectar Biosciences Inc. a good long term investmentConsistently exceptional gains - Autocar Professional
Cellectar’s Cancer Therapy Hopes Face A Cash Crunch - Finimize
What makes Cellectar Biosciences Inc. stock price move sharplySafety First Trading Signals - Newser
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN
How Cellectar Biosciences Inc. stock performs during market volatilityRapid Gain Targets - Newser
Why Cellectar Biosciences Inc. stock attracts strong analyst attentionFree Stock Market Return Analysis - Newser
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - GlobeNewswire Inc.
Sequoia Financial Advisors LLC Purchases 188,760 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences shares rise 3.59% premarket after closing $6.9 million public offering. - AInvest
Cellectar Biosciences Closes $6.9 Million Public Offering - MarketScreener
Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development - Quiver Quantitative
Cellectar Biosciences Announces Closing of $6.9 Million - GlobeNewswire
Cellectar Secures $6.9M Funding: Healthcare Funds Back New Breast Cancer Drug Development - Stock Titan
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News - GuruFocus
Cellectar Biosciences prices $6 million public offering - Investing.com
Cellectar Biosciences, Inc. Announces Pricing of Underwritten Public Offering for Approximately $6 Million - Quiver Quantitative
Cellectar Biosciences prices $6 million public offering By Investing.com - Investing.com Canada
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch - The Globe and Mail
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Sell at Wall Street Zen - Defense World
Cellectar Biosciences, Inc. and Nusano Enter into Multi-Isotope Supply Agreement - MarketScreener
Cellectar Biosciences provides update on clinical programs and preclinical data - Investing.com
Cellectar and Nusano sign multi-year radioisotope supply agreement By Investing.com - Investing.com India
Cellectar Biosciences enacts one-for-thirty reverse stock split on Nasdaq - Investing.com UK
Cellectar Biosciences (CLRB) Submits Study Protocol to FDA for P - GuruFocus
Cellectar Biosciences Trading Halted: News Pending - AInvest
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - The Manila Times
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq
Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World
Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks
Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire
Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cellectar Biosciences Inc-Aktie (CLRB) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):